Abiopharma

Vir Biotechnology - Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones

Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor

Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City

Nuvation Bio Inc. - Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference

Profound Surpasses 2025 TULSA-PRO® Installed Base Goal

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

Atara Biotherapeutics Provides Regulatory and Business Update onEBVALLO™ (tabelecleucel)

KORU Medical Systems Reports Preliminary Q4 and Full Year 2025 Results; Achieves Record Revenue and Full Year Positive Operating Cash Flow

Cabaletta Bio Announces 2026 Strategic Priorities

Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026